key: cord-0981163-bw6u3189
authors: Cravedi, Paolo; Schold, Jesse D.; Safa, Kassem; Kates, Olivia S.; Elfadawy, Nissreen; Mannon, Roslyn B; Shah, Malay B.; Hammond, Sarah P; Avery, Robin; Guerrero Miranda, Cesar; Riella, Leonardo V.; Jowsey‐Gregoire, Sheila; Akalin, Enver; Camirand, Geoffrey; Alegre, Maria‐Luisa; Azzi, Jamil
title: The COVID‐19 Pandemic: A community approach
date: 2020-08-06
journal: Clin Transplant
DOI: 10.1111/ctr.14059
sha: 44397fa8cfba8de6a9869c1092450e0e91a0f9c2
doc_id: 981163
cord_uid: bw6u3189

An unprecedented global pandemic caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) has quickly overwhelmed the health care systems worldwide. While there is an absence of consensus among the community in how to manage solid organ transplant recipients and donors, a platform provided by the American Society of Transplantation online community “Outstanding Questions in Transplantation”, hosted a collaborative multicenter, multinational discussions to share knowledge in a rapidly evolving global situation. Here, we present a summary of the discussion in addition to the latest published literature.

disruptions on operations pertinent to donors, recipients, as well as transplant professionals led to a significant decrease in the chance to obtain a transplant in a timely fashion and placed the post-transplant follow-up in significant jeopardy.

Our understanding of COVID-19 pathophysiology has grown quickly, but many questions remain unanswered. A large number of clinical trials has been initiated with results that have already helped clinical decision-making in some cases. However, even with this progression, there is still no well-established treatment for this condition. To date, published information regarding the incidence and clinical course of COVID-19 in transplant recipients has primarily been in the form of case reports and case series. While these are valuable, larger multicenter and comparative studies are awaited in order to determine the optimal management of COVID-19 in transplant recipients, who constitute a potentially highrisk population due to their ongoing immunosuppression and higher incidence of comorbidities. 2, 3 These uncertainties have fueled anxiety and have ignited an urgent need for further information and discussion.

In July 2017, the Community of Transplant Scientists (COTS) within the American Society of Transplantation (AST) created an online community called "Outstanding Questions in Transplantation", a platform that allows clinicians and scientists to meet and exchange ideas about current challenges in the transplantation field. We launched the SARS-Cov-2 pandemic discussion in March 2020 in response to the increasing number of cases in the United States. It was awe-inspiring to see members from China, Europe and the US front-lines come together to exchange experiences, frame questions and try to find answers to the unprecedented challenges imposed by the worst pandemic of the last century. To date, the total number of posts on this topic is over 750 with almost 300 unique contributors. We are grateful to all the participants in this lively exchange.

In this paper, we have summarized the AST discussion in addition to the latest published literature, dividing it into six major areas of interest: epidemiology, pathophysiology, prevention, logistics, management of immunosuppressive therapies and treatment. The

This article is protected by copyright. All rights reserved discussion started March 13 th 2020 and continued until the date of this paper's preparation in May 27 th . While this discussion was primarily US based, many members from China and Europe participated in the discussion as well. This does not represent an endorsed AST guidelines nor does it constitute a comprehensive evidence-based review.

As of June, 2020 over eight million confirmed cases of COVID-19 have been reported globally with over 445,000 associated deaths. 4 SARS-CoV-2 is known to be transmitted through respiratory droplets 5 and remains viable in aerosols and surfaces, 6 This observation suggests that multiple routes of transmission are possible for this virus. The majority of affected individuals have mild symptoms thus making accurate identifications of the disease very challenging; indeed, individuals infected with SARS-CoV-2 are asymptomatic for a median of 5.1 days and nearly all individuals who develop symptoms do so within a median of 12 days. 7, 8 Due to the high rate of asymptomatic or pre-symptomatic infection and limited availability of testing, the true prevalence of COVID-19 is unknown and is likely underestimated significantly based on confirmed cases alone. A population-based study in Iceland 9 found that 13.3% of individuals targeted for testing based on symptoms tested positive for SARS-CoV-2, but so did 0.8% of asymptomatic individuals in the population, with higher rates among males and adults. 9 Early reports indicated that older age and medical comorbidities were more common among documented cases of COVID-19. 10 Risk factors for severe disease among those affected with COVID-19, estimated to be 14% of cases, are still being elucidated. In a cohort of more than 4,000 patients in New York City, risk factors for hospitalization included older age, morbid obesity and heart failure. 11 At this time, the disease prevalence in organ transplant recipients is unknown. Experience with prior coronavirus outbreaks suggests that transplant recipients may have higher susceptibility to infection, higher risk of severe disease, and prolonged shedding of potentially infectious virus. 12 Transplant recipients may also be at higher risk of secondary infectious complications. Several case series describing COVID-19 in transplant recipients have been published with the largest series from New York City. 3, 13, 14 In the New York

This article is protected by copyright. All rights reserved Presbyterian hospital system, 90 solid organ transplant recipients were diagnosed with   SARS-CoV-2 infection, with 30% having severe disease. 44 patients were non-kidney   transplant recipients (17 lungs, 13 livers, 9 hearts, and 5 dual-organ). Risk factors for severe disease were hypertension and active malignancy. Overall case fatality was 24%, and 22% of patients remained hospitalized at the time of reporting. 14 At Montefiore Medical Center, among a population of 36 kidney transplant recipients hospitalized with COVID-19, there was a 28% mortality rate at 3 weeks. 13 Additional small series from China, Italy, France, and the U.S. highlight a lower frequency of fever at presentation, some presentations without typical respiratory symptoms, and a range of clinical severity. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] In several series, mortality appears to correlate with the presence of advanced age and comorbid conditions. 27-31

The effects of COVID-19 have also exacerbated healthcare disparities to vulnerable groups in the US population. Across the nation, especially in large cities, the majority of patients and the highest mortality have been observed in Blacks and Hispanics mainly due to what is thought to be a lack of "social distancing privilege". 32 This observation holds true in SOT recipients with COVID-19: In the New York city cohort, 29 out of 36 kidney transplant recipient with COVID -19 were black or Hispanic. 13 The epidemiology of the unprecedented COVID-19 pandemic is unique, and timely dissemination of information concerning this novel virus will be critical to coordinate an appropriate response.

Coronaviruses are spherical virions with a core shell and surface projections. They have large (30-kb) single-stranded, positive-sense RNA genomes. The surface spike glycoprotein (S protein) on the surface of the virus binds to the receptor Angiotensin Converting Enzyme 2 (ACE2). ACE2 is expressed in many organs, including the bronchus and lung parenchyma, heart, kidney, and gastrointestinal tract. 33 After binding to the

This article is protected by copyright. All rights reserved receptor, a nearby host protease cleaves the spike glycoprotein, facilitating virus entry. 33 Endosomal cell entry of SARS-CoV-2 is facilitated by a low pH and pH-dependent endosomal cysteine protease cathepsins. Once inside cells, SARS-CoV-2 exploits the endogenous transcriptional machinery of the host cell to replicate and spread throughout the entire lung. 33 The pathophysiology of COVID-19 is still poorly understood. Infected cells release mediators and chemokines that rapidly recruit neutrophils. While such neutrophils may limit viral spread, they also secrete cytokines and chemokines that attract further immune cells such as monocytes and T cells, fueling the exaggerated immune responses that may lead to cytokine storm, ARDS, and multi organ failure.

Complement activation has also been described in SARS-CoV-2 infected patients, a phenomenon possibly implicated in the pathogenesis of acute lung injury and ARDS. Gao et al., identified MBL-associated serine protease-2 (MASP-2) as the target of the N-proteins for SARS-CoV-2. 34 The lung injury induced by other known coronaviruses in mice was attenuated when either the N-protein-binding motif was truncated, the MASP-2: N-protein interaction was pharmacologically blocked, or MASP-2 was knocked out. Preliminary data from patients treated with an anti-complement C5a blocking antibody suggest a potential benefit of complement targeting therapies in COVID-19 patients with severe lung injuries. 34 Patients with severe COVID-19 have higher plasma levels of IL-6, IL-10, and TNF-α and fewer circulating CD4 and CD8 T cells than individuals with mild disease or healthy controls. 35 Lymphocytopenia may be mediated by TNF-α which can promote T cell apoptosis. Similarly, the cytokine storm can promote apoptosis or necrosis of T cells, and consequently lead to their reduction. 36 This trend is even stronger in elderly patients.

Intriguingly, the most severe COVID-19 cases also have increased percentages of T cells with an exhausted phenotype. However, it is not clear if the T cell exhaustion is due to the persistence of the virus, the type of inflammation elicited by the virus, or both. 37 The durability of neutralizing antibody responses against SARS-CoV-2 currently remains unknown. The discussants pointed out that "antibody responses to COVID-19, like other virally mediated pulmonary diseases (including MERS, SARS, and RSV) may reduce viral

This article is protected by copyright. All rights reserved replication, but also may not reliably prevent infection, and more importantly appear to mediate marked pulmonary inflammation. These observations are critically important, as pulmonary inflammation is the primary mediator of death from these diseases. In fact, the primary reason that vaccines for RSV have failed is that children who received the vaccine, and subsequently acquired RSV, had much higher death risk due to pulmonary inflammation, whereas those children who were not vaccinated had minimal risk of inflammation". Current research investigates whether neutralizing antibodies may preferentially prevent viral replication whereas non-neutralizing antibodies may enhance inflammation and immunopathology, perhaps via immune complex-based activation of innate immune cells. There are all very relevant issues that should be carefully considered in the follow-up of patients who recovered after SARS-CoV-2 infection.

Prevention of viral spread is a major focus of all medical facilities impacting both patients and health care workers (HCW). While viral spread was thought initially to be primarily through contact with an infected individual from the primary infection zone, it has become obvious that there is community spread of SARS-CoV-2 from asymptomatic infected individuals. Hence, most agree that the rules to prevent viral infection in the general population would apply to transplant patients. 5 Inpatient: For inpatient care, more extensive preparation has been recommended including rescheduling elective surgery, shifting urgent inpatient diagnostic and surgical procedures to outpatient settings, limiting visitors to the hospital, and creating surge space to manage known or suspected COVID-19 patients. 5 The modified Traffic Control Bundling Accepted Article (HCW) . Also, HCWs must have gowns, gloves and eye protection along with N-95 masks upon entering these two zones. As HCWs transition between different zones, they engage in hand disinfection with 75% alcohol and use adequate PPE. 38 Outpatient: Critical to facilities planning is the foresight that transplant patients with potential COVID-19 infection may require immediate care management far from the Transplant Center. As Transplant Centers in high prevalence areas have implemented their emergency care plans, they may be unable to accept patients in transfer or provide acute outpatient management. Separation of immunosuppressed/immunocompromised patients from COVID-19 infected patients on site has been implemented in some facilities that have sufficient space and resources. Moreover, non-COVID-19 urgent care may be required in transplant recipients, again, at a distance from their typical transplant center. Planning for phone triage, telehealth and electronic consultations are important steps for academic medical centers that may be overrun with acutely ill infected patients.

only to avoid patient-to-patient transmission, but also transmission to health care workers .

recommendations include eye protection, gowns, gloves, and N95 respirators. 40 Personal powered air purifying respirators (PAPRs), previously specified by federal standards for high-hazard procedures, are of limited availability and may be implemented in high risk situations such as bronchoscopy or intubation. Moreover, as data emerges from other endemic locations across the world, 41 it is apparent that there is clear environmental contamination that supports the use of social distancing and other environmental controls.

This has implications for patients and healthcare providers outside of healthcare settings: any provider could potentially be exposed to COVID-19 and act as vectors for disease transmission to the community. Such data supports our recommendation for patients and provider to practice "social distancing" and self-isolation if a known exposure occurs.

This article is protected by copyright. All rights reserved

Due to COVID-19 concerns and visitor restrictions to most clinics, most transplant centers have rescheduled in-person visits for stable patients. Initially, the majority of transplant centers cancelled outreach clinics, particularly those that required flights. In place of inperson visits, HIPAA compliant telecommunication technologies utilizing electronic medical record systems have allowed for early implementation or expansion of telemedicine programs, thus minimizing the risk of COVID-19 transmission. Many aspects of coordination of patient care, including scheduling and nurse coordinator responsibilities, have been shifted to remote work-stations and virtual meetings. Many staff meetings and daily briefings have been converted to telecommunication meetings and webinars. As COVID-19 disease cases have begun to stabilize in many communities, in-person and outreach clinics have begun to re-open. However, telemedicine continues to remain an option for many patients, and centers are better understanding how to fully and efficiently implement these technologies on a more routine basis.

As a general rule, most agree that living donor transplant should not place unnecessary and additional risk to the donor. Early in the outbreak period, The Transplantation Society made the following recommendations: 42 1. In communities with widespread transmission, temporary suspension of the living donor kidney and liver programs should be considered.

CoV-2 should be ruled out.

3. Living donation should not be performed on either the donor or recipient who has returned from places with a high incidence of infection or has been exposed to another individual with confirmed or suspected COVID-19 within 14 days.

It is worth noting that since these recommendations were made, the incidence of COVID-19 has continued to rise throughout the world. In fact, the United States has quickly developed to have the highest number of cases in the world. 43 While COVID-19 testing capacity has increased significantly, the true prevalence and incidence of the SARS-CoV-2 virus is not yet known in the US. Therefore, considering that kidney/liver living donation is not thought of as life-saving in the short-term, many transplant centers in the US initially suspended their living donor programs. The rationale behind suspension of living donors programs included: 1) ensure donor and recipient safety by minimizing unnecessary exposure, and 2) minimize the utilization of hospital capacity should a spike in COVID-19 cases begins to challenge resources.

However, as transplant centers and hospital systems have started to understand disease prevalence within their own communities, many have recently re-started their living donor programs. It is recommended to screen the living donor and recipient candidates for SARS-CoV-2 prior to proceeding to the operating room. If negative, a thorough discussion should be initiated with the donor and recipient regarding the risks and benefits of such a procedure with consideration for this still evolving pandemic.

Kidney transplantation is not thought to be lifesaving in the short-term, so there needs to be consideration for not performing these procedures if hospital resource utilization has been stretched due to an influx of COVID-19 patients. During the initial phases of this pandemic, many programs in the United States were transplanting kidneys in patients who were highly sensitized or where a potential donor has a zero-antigen mismatch. Additionally, many patients received kidneys with a low risk of delayed graft function, as these patients were discharged from the hospital within a few post-operative days. Consideration for switching from lymphocyte depleting agent induction to basiliximab should be given for low risk patients. Many programs continued to transplant liver, hearts and lungs unless maximal hospital resource utilization was occurring in those centers where COVID-19 was prevalent.

This article is protected by copyright. All rights reserved At the present time, many programs have returned to previous practices of kidney, liver, heart, and lung transplant. Many centers have implemented a COVID-19 screening for all recipients when they are called in for transplantation. We recognize that not all centers have access to rapid screening tests that will result within a few hours of testing. At minimum, we would recommend COVID-19 screening for all potential recipients if they are currently hospitalized at the time of organ offer.

While the true prevalence of disease is still not known, the majority of organ procurement organizations are performing COVID-19 screens on all donors. Recognizing that current COVID-19 screens continue to have a high false negative rate, 44 Huang et al detected SARS-CoV-2 RNA in the blood of 15% (6/41) critically ill patients in Wuhan, China, raising the concern for potential bloodstream viral transmission to recipients of infected tissue donors. 36 An autopsy on COVID-19 patient showed hepatocellular, renal, and cardiac damage at several degrees. 47 A case report of a COVID-19 patient in cardiogenic shock and myocarditis required VA-ECMO was notably for the presence of viral

This article is protected by copyright. All rights reserved particles in the endomyocardial biopsy. 48 In a retrospective study, 6.9% of patients with COVID-19 have positive SARS-CoV-2 RNA in the urine; 49 in another study, 29% of patients (44/153) patients have positive SARS-CoV-2 RNA in the stool. 50

There are a number of ways that health care providers can maintain mental well-being in the face of a pandemic and thus be better equipped to care for infected patients. A key strategy includes having an understanding of Psychological First Aid which is a technique that has been developed to reduce distress in a disaster situation. 51 The priorities identified in the Psychological First Aid model include: ensuring the safety of individuals affected by disaster followed by connecting these individuals with their families and support networks. Additionally, it is essential to provide a calm presence to combat the impact of panic with an emphasis on helping the afflicted and their providers to maintain their own needs such as sleep, nutrition and taking breaks and using existing resources to triage those in need of additional services. Thus far, the limited medical literature related to COVID-19 suggests significant stress and post-traumatic stress disorder (PTSD) for those on the frontline of the pandemic, 52 further emphasizing the need for self-care for health care providers.

Resilient coping strategies have been identified and likely would mitigate the impact of COVID-related stressors. The following resilient coping strategies have been identified and include: optimism, problem solving, flexibility, acceptance, providing help to others, exercise, maintaining social support networks, emulating resilient role models, philosophical or spiritual resources, and humor. 53

Social isolation and uncertainty are likely contributing factors to the anxiety and distress experienced by individuals who are required to social distance to help prevent the spread of Accepted Article the virus. 54 Previous research suggests that those who are quarantined are at increased risk for psychological distress. 55 One study suggested that those who are sheltering at home with their family are not likely to experience marked distress. 56 Providing additional support to staff members who are isolated or quarantined is warranted including strategies such as emphasizing the importance of staying connected with their primary support network, Many concerns were raised on the hub regarding the need for clinical trials to identify the best practices to manage immunosuppressive therapies in our population. While

This article is protected by copyright. All rights reserved reducing immunosuppression can improve potential immunity against the virus; a significant reduction could potentially exacerbate hyperinflammation and result in aberrant cytokine release.

No therapeutic agents or vaccines have been FDA approved to treat or prevent COVID-19

to-date. 61 

This article is protected by copyright. All rights reserved

Lopinavir-ritonavir is a protease inhibitor approved to treat HIV. 62 Despite initial promising results from uncontrolled studies, a Chinese clinical trial (ChiC-TR2000029308) in 199 patients with COVID-19 pneumonia showed that treatment with lopinavir-ritonavir with standard supportive care compared to standard care alone was not associated with a significant difference in the time to clinical improvement or mortality. 62 

SARS-CoV-2 needs an endosomal acid pH for processing and internalization. 67 In vitro data indicate that the antimalarial drug chloroquine exerts antiviral effects by increasing endosomal pH and abrogating virus-endosome fusion. Hydroxychloroquine is an oral derivative of chloroquine that has fewer side effects. Besides its antiviral activity, hydroxychloroquine has an immune-modulating activity, which may synergistically enhance its antiviral effect in vivo. 68 Early clinical interest and significant debate among OQT respondents was spurred by two non-randomized French studies that suggested potential

This article is protected by copyright. All rights reserved efficacy of hydroxychloroquine, in rapid viral clearance, possibly in combination with azithromycin. 69, 70 Several recent peer-reviewed observational and large registry studies have suggested chloroquine and hydroxychloroquine may have no impact and may even increase mortality. An observational study of hydroxychloroquine in 1446 patients cared for at a large medical center in New York City that used propensity score matching found no association between hydroxychloroquine use and the composite risk of death or intubation. 71 Furthermore, in another recent multicenter retrospective cohort study of 1438 patients hospitalized in New York state with COVID-19 there was no difference in in-hospital mortality among patients on no treatment compared to those on hydroxychloroquine, hydroxychloroquine with azithromycin, or azithromycin alone. 72 A recent randomized controlled trial in 821 asymptomatic participants at high-risk or moderate-risk exposure to Covid-19 showed no benefit of hydroxychloroquine in preventing disease. 73 Overall, these data do not support the use of these treatments in COVID-19 patients, including organ recipients.

Remdesivir is an adenosine analogue with a broad-spectrum antiviral effect as an inhibitor of viral RNA polymerases. 74 It incorporates into nascent viral RNA chains and results in premature termination. 74 Remdesivir inhibits SARS-CoV-2 in vitro 68 Grein, et al. reported promising clinical outcomes among 53 patients with severe illness due to COVID-19, more than half of whom required mechanical ventilation, treated with one or more doses of remdesivir for compassionate use. 75 Even more compelling are the preliminary results of a randomized blinded trial of remdesivir for the treatment of COVID-19 in 1063 patients with evidence of lower respiratory tract infection. 76 Patients treated with remdesivir had a shortened recovery time of 11 days compared to 15 in the placebo group. Numerically, there were fewer deaths by day 14 among those treated with remdesivir (7.1% vs. 11.9%) but it did not meet statistical significance. Serious adverse events were similar between the two groups. Remdesivir is currently being studied in other clinical trials, and results from those Accepted Article randomized trials and the final results of the trial above, should shed more light on its efficacy.

The use of convalescent plasma was recommended as an empirical treatment during 

This article is protected by copyright. All rights reserved treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. A single-center, randomized, open-label, controlled trial, will evaluate the efficacy and safety of IVIG therapy in patients with pneumonia caused by SARS-CoV-2 (NCT04261426).

Based on the reports of potential utility of convalescent plasma, multiple efforts are underway to identify neutralizing antibodies within this plasma, and to develop monoclonal antibodies with specific anti-SARS-CoV-2 activity. Future clinical trials are expected.

The use of high dose corticosteroids remains unclear and subject of debate in the setting of COVID-19. The rationale behind using corticosteroids is to decrease inflammatory response in the lungs. However, it also has the potential to delay viral clearance and increase risk of 

This article is protected by copyright. All rights reserved Patients with severe COVID-19 pneumonia show increased levels of circulating IL-6. An early manuscript detailing outcomes in 21 patients with severe pneumonia due to COVID-19 treated with tocilizumab, a recombinant humanized monoclonal antibody against the human IL-6 receptor, that reported improvements in fever, oxygen requirements and inflammatory markers sparked considerable interest in the use of drugs that block the effects of IL-6. 84 Tocilizumab is used for rheumatoid arthritis, and also used in treatment of cytokine-release York City, reported on 90 SOT recipients with COVID-19, of whom 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. 86 Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU). The 16 patients who received tocilizumab included 6 with moderate and 8 with severe disease, but the authors commented that no firm conclusions could be drawn about the effects of any one therapeutic modality. 14 

This article is protected by copyright. All rights reserved progress to ascertain the effects of this therapy and the optimal timing, if given. There is are also ongoing discussions about the optimal anti-infective monitoring and prophylaxis in the aftermath of tocilizumab administration, or other similar therapies, given the potential for secondary infections.

The Janus kinase (JAK) inhibitors ruxolitinib (NCT04362137, others) and baracitinib (NCT04373044, others) are currently under study for their potential to reduce cytokine release in the inflammatory phase of COVID-19. Baracitinib may also have antiviral effects (NCT04390464). 87 Other immunomodulatory therapies that have been used off-label or are in clinical trials for COVID-19, for protection against pulmonary injury and inflammatory progression, include the Bruton tyrosine kinase inhibitors ibrutinib 88 and acalabrutinib (NCT04380688) complement inhibitors eculizumab (NCT04346797) and ravulizumab (NCT04390464), and the CCR5 inhibitor leronlimab (NCT04343651). 13 This is only a partial list, and there are many other agents of potential interest. Further reports on the effects of these or other immunomodulatory therapies on transplant recipients will be valuable, as it is not possible to generalize from effects in the overall population with COVID-19.

Angiotensin-converting enzyme 2 (ACE2), the receptor for SARS-CoV-2, is a membranebound aminopeptidase that cleaves angiotensin I and angiotensin II into the angiotensin-(1-9) and angiotensin-(1-7) peptides. 67 This, together with higher disease severity in individuals with diabetes or cardiovascular disease who are often in therapy with renin angiotensin system (RAS) inhibitors, raised concerns about the use of these drugs that may alter ACE2 expression.

In response to some media sources and health systems that have recently called for the discontinuation of RAS inhibitors, the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) have emphasized the lack of any evidence to support discontinuation of RAS inhibitors in the context of the pandemic COVID-19 outbreak. 89-91

This article is protected by copyright. All rights reserved Therefore, RAS inhibitor withdrawal both prophylactically and in the context of suspected COVID-19, is not advised and may be harmful in certain high-risk patients with known or suspected COVID-19. There is a single-center randomized clinical trial in progress, to assess whether administration of prazosin might prevent cytokine storm in COVID-19 (NCT04365257).

In all new candidate therapies for COVID-19, whether antiviral therapies, passive immunity, immunomodulatory therapies, or future vaccine trials, the OQT respondents generally agreed that it will be extremely important to assess the risks and benefits in transplant recipients, given special considerations in their infection risk and complex immunologic status What is needed to reopen transplantation programs?

With the pressing need of growing wait lists for recipients even during the pandemic, and ongoing urgent needs for hearts, lungs and livers, transplant programs have been considering this question since the onset of closures of their medical centers. However, the Centers for Medicare and Medicaid Services had designated transplantation as a Tier 3B surgical procedure (akin to trauma and urgent vascular procedures) and as such, an essential service. Hence, while transplantation fell to all-time lows during April 2020, transplantation did not come to a halt entirely. As already noted, while living donation closed down to barely perceptible volumes, even these programs have begun reopening.

Deceased donor transplantation has been ongoing, while not at a robust volume as in pre-COVID19 days. Clearly the variability of disease prevalence is contributing to varied approaches to program functions, not unlike that seen in the general public. This question was recently addressed by the consortium of transplant professional groups across the world 92 and two issues emerged: personnel safety and patient safety.

In regards to programmatic safety, transplant practices have changed throughout the pandemic. 58 In a survey study of nearly 80% of transplant centers in the US, programs offered concerns regarding resources during the pandemic with regards to safety including ventilators, OR and anesthesia staff availability, ICU beds, PPE, and sufficient patient Accepted Article testing. Additional recommendations were voiced by ASTS including avoiding OR presence during intubation for the transplant team, and recognition that other contributing factors such as aerosolized spread via laparoscopic procedures, and electrocautery highlighted in a recent webinar of transplant experts. 93 Patient testing continues to be paramount to management, with recognized limitations to current testing tools and limited data regarding RNA persistence and viral replication post initial infection. 94 Hence, a positive PCR test may remain positive for several days post initial symptomatic infection, and centers need to determine their risk threshold to proceed, and how frequently to test post operatively.

Testing of potential recipients pre-transplant appears to be a standard practice in all solid organ transplants. 95 A second aspect is organs for donation. For living donations, some transplant programs continued throughout the pandemic with a low point of 11 during the week of April 5, 2020 96 and currently on the upswing. Program activity is focal and regional, in areas where the pandemic has been less severe and based on risk acceptance thresholds as recently demonstrated. 97 Programs depend on the ability to access testing for living donors and recipients prior to transplantation with guidelines for this pre-donation testing for both living and deceased donors. 98 Furthermore, for deceased donor organs, OPO's have had to adapt to fluctuating organ availability and limiting retrieval team access in and out of endemic hotspots. 99 All potential donors are being tested for COVID-19 using Broncho-alveolar lavage (BAL), endotracheal aspirate and nasal swabs with good accuracy of results. 100 The current practice is to not utilize donors that are SARS-COV2 positive due to concerns of transmission risk although this has recently been debated. 45 101 Additionally, transplant center's need to assure follow-up plans utilizing robust Telehealth interactions have been implemented universally. With the implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, as signed into law by the President on March 6, 2020, certain Medicare telehealth payment requirements during the Public Health Emergency (PHE) have been waived to allow beneficiaries in all areas of the country to receive telehealth services. Barriers in implementation for transplantation have been recently outlined. 102 Additionally, frequent lab monitoring may include home visits or local lab collection and several commercial entities have added this service to their portfolios

This article is protected by copyright. All rights reserved to include immune monitoring with the overarching goal to limit patient access into the medical center and prevent unnecessary exposure. 60

Informed consent allows recipients and their family members to fully consider the risks and benefits of accepting a donor organ and was noted to be an area of concern in the discussions by the group. A reasonable approach that would allow for a balanced view of both the risks and benefits of organ donation in the area of COVID 19 was articulated during a discussion about restarting programs. The following suggestions were proposed to provide transparency for the recipients and their families including: ensuring the donor tested negative, discussing the chances of a false positive test for the donor, ensuring that the donor had no symptoms suggestive of COVID, weighing the risk of undetected infections against the risk of waiting longer for a donor organ, acknowledging that the medical community never has perfect knowledge of all risks or the magnitude of known risks, and ensuring that the staff taking care of patients in the ICU wore PPE and were appropriately trained to minimize the risk of transmission. These suggestions demonstrate the need for sufficient time with recipients and family members for thorough and thoughtful conversations to answer questions and address their concerns while recognizing the limits of knowledge in this rapidly changing era.

We are grateful to the AST members who provided guidance and participated in the discussions and to AJT for publishing the highlights of this initiative. The above summary reflects vigorous discussions on COVID-19-related topics among many AST members, within the email framework of "Outstanding Questions in Transplantation," and does not constitute a guideline or a systematic review of evidence. It is likely that recommendations will change, and that formal guidelines will be created in the future, as more evidence from randomized trials and other clinical experience emerges. However, this does illustrate the

This article is protected by copyright. All rights reserved value of ongoing collaborative multicenter, multinational discussions in sharing knowledge in a rapidly evolving global situation.

WHO Declares COVID-19 a Pandemic

Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia

Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York

The COVID-19 Pandemic in the US: A Clinical Update

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

The Incubation Period of Coronavirus Disease

From Publicly Reported Confirmed Cases: Estimation and Application

Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19

Spread of SARS-CoV-2 in the Icelandic Population

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City

Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients

Covid-19 and Kidney Transplantation

COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter

Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States

COVID-19: Yet Another Coronavirus Challenge in Transplantation. The Journal of Heart and Lung Transplantation

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

A familial cluster, including a kidney transplant recipient

SARS Cov2 infection in a renal transplanted patients. A case report

Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient

Identification of Kidney Transplant Recipients with Coronavirus Disease

COVID-19 in a Kidney Transplant Patient

Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report

First case of COVID-19 in a kidney transplant recipient treated with belatacept

Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report

Fatal outcome in a liver transplant recipient with COVID-19

COVID-19 and African Americans

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)

Protecting Health Care Workers during the COVID-19

Coronavirus Outbreak -Lessons from Taiwan's SARS response

Taiwan's traffic control bundle and the elimination of nosocomial severe acute respiratory syndrome among healthcare workers

Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus

From a Symptomatic Patient

COVID-19) for Transplant Clinicians

COVID-19 Dashboard. Johns Hopkins Coronavirus Resource Center

False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications

Use of SARS-CoV-2 infected deceased organ donors: Should we always "just say no?

COVID-19: A global transplant perspective on successfully navigating a pandemic

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

The Potential Efficacy of Psychological First Aid on Self-Reported Anxiety and Mood: A Pilot Study

Factors Associated with Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus

Accepted Article This article is protected by copyright. All rights reserved

Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress

in Social Distancing, quarantine and Isolation in Psychiatry of Pandemics: A Mental Health Response to Infection Outbreak

SARS control and psychological effects of quarantine

Shelter-in-place and mental health: an analogue study of well-being and distress

SARS-CoV-2 Pandemic and The Need for Transplantoriented Trials

Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States

Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus

Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics

Accepted Article This article is protected by copyright. All rights reserved 67. Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

One-week, two-visit, double-dose, intra-dermal (2(2)ID) rabies vaccination schedule for travelers: Time/dose sparing, effective but "off label

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Convalescent plasma treatment of severe COVID-19: A matched control study

All rights reserved 81

SARS: systematic review of treatment effects

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Effective treatment of severe COVID-19 patients with tocilizumab

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Challenges in Heart Transplantation in the Era of COVID-19

Accepted Article This article is protected by copyright. All rights reserved 97

SARS Cov-2 infection in a renal-transplanted patient: A case report

The Role of Telemedicine in Kidney Transplantation: Opportunities and Challenges

This manuscript is a work product of the American Society of Transplantation's Outstanding Questions in Transplantation Research online community hub. We would like to thank all our members who contributed to the discussion. We would like to thank the American Society of 

This article is protected by copyright. All rights reserved

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved